GlassScriptPhysician profile
Eka Ini Omowa
NPI 1417611898
$4,459.02
in general payments reported to CMS, 2019-2025
22 companies · $856 in 2025
The $856 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.59 · 2022: $328 · 2023: $1,226 · 2024: $2,037 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,119.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $686.74 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $648.56 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $570.76 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $436.72 | 2023-2025 | |
| Tris Pharma INC | $330.86 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Lundbeck LLC | $304.92 | 2022-2025 | Rexulti, Brintellix, Abilify Maintena |
| Ironshore Pharmaceuticals INC. | $175.02 | 2022-2024 | |
| Vanda Pharmaceuticals INC. | $169.99 | 2024-2025 | Fanapt, Hetlioz |
| Corium, LLC | $162.01 | 2022-2025 | Azstarys |
| Noven Therapeutics, LLC | $129.22 | 2023-2025 | Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $128.57 | 2021-2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $119.02 | 2022-2024 | Quviviq |
| Alkermes, INC. | $116.68 | 2023-2024 | Aristada, Lybalvi |
| Bausch Health US, LLC | $92.21 | 2023-2024 | Aplenzin, Wellbutrin |
| Teva Pharmaceuticals USA, INC. | $78.12 | 2023 | Austedo Xr, Uzedy, Austedo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $71.40 | 2024-2025 | Auvelity |
| Almatica Pharma LLC | $63.88 | 2024 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $59.76 | 2023-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $52.92 | 2024 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $24.76 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $23.52 | 2025 | Jornay Pm |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.38 | 2024 | Rexulti, Abilify Maintena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eka Omowa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.